# Delix Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delix-therapeutics

- Industry: Biotechnology
- Headquarters: Concord, US
- Website: www.delixtherapeutics.com
- Total disclosed funding: $80M
- Latest round: Series A (Sep 27, 2021)
- Investors on record: 11

## About

Based in the US, Delix Therapeutics, Inc. specializes in developing neuroplastogens, a novel class of therapeutics aimed at enhancing brain health and addressing neuropsychiatric conditions effectively and safely.Delix Therapeutics, Inc. is focused on creating innovative treatments for mental health issues through the development of neuroplastogens. The company is headquartered in Concord, US. Founded by Nick Haft, the company has recently raised USD 30 mn in VENTURE DEBT funding on January 10, 2022, contributing to a total of USD 71.62 mn raised to date through a total of 4 deals.Delix Therapeutics is pioneering a new class of therapeutics known as neuroplastogens, designed to enhance brain health. These compounds leverage the brain's inherent capacity for neuroplasticity, aiming to repair and improve the physical structure of brain cells. By doing so, Delix targets a variety of neuropsychiatric conditions, seeking to provide treatments that are safe, fast-acting, and long-lasting. The company’s core offerings focus on developing novel therapeutics that can alleviate prevalent mental health issues, thereby serving a diverse clientele, including healthcare providers and mental health practitioners. Delix’s products are primarily marketed in North America and Europe, where the demand for innovative brain health solutions continues to grow.Delix Therapeutics operates with a focus on ensuring consistent revenue through partnerships with healthcare institutions and direct sales to medical facilities. The company’s transaction structure involves B2B relationships, where products are supplied to healthcare providers who then administer them to patients requiring mental health interventions. Revenue is generated through the sales of their flagship neuroplastogen compounds, which are integrated into treatment protocols by clinicians. The pricing structure reflects the premium nature of these therapeutics, aligning with the advanced scientific research and development backing the products. The company is positioned to capitalize on the increasing market demand for effective brain health treatments, thereby establishing a robust revenue stream through its innovative offerings.Delix Therapeutics plans to utilize the recent USD 30 mn raised in VENTURE DEBT funding to boost its drug development program and expand its pipeline of novel neuroplasticity-promoting therapeutics throughout 2022. The company aims to grow its team and pursue additional strategic opportunities to enhance its market presence. Delix is also targeting expansion into new geographic regions to broaden access to its therapeutics, aiming to establish a foothold in additional markets by late 2023.

## Funding rounds

- Series A, Sep 27, 2021, $72M — ARTIS Ventures, RA Capital Management, Vertical Venture Partners, Cover2 Ventures, Presight Capital, OMX Ventures, re.Mind Capital, WPSS Investments, Palo Santo Venture Fund, PsyMed Ventures, Saya Bio
- Seed, Sep 4, 2020, $8M — Presight Capital, OMX Ventures

## Investors

- Presight Capital — Seed, Series A
- OMX Ventures (https://capitalatlas.ai/funds/omx-ventures) — Seed, Series A
- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series A
- Cover2 Ventures — Series A
- re.Mind Capital (https://capitalatlas.ai/funds/re-mind-capital) — Series A
- WPSS Investments (https://capitalatlas.ai/funds/wpss-investments) — Series A
- Palo Santo Venture Fund (https://capitalatlas.ai/funds/palo-santo-venture-fund) — Series A
- PsyMed Ventures (https://capitalatlas.ai/funds/psymed-ventures) — Series A
- Saya Bio (https://capitalatlas.ai/funds/saya-bio) — Series A